AU2004285562B2

AU2004285562B2 - Pigment epithelium-derived factor, novel biological activity and methods of use

Pigment epithelium-derived factor, novel biological activity and methods of use Download PDF

Info

Publication number: AU2004285562B2
Authority: AU; Australia
Prior art keywords: pedf; peptide; vegf; amino acid; cells
Prior art date: 2003-10-29
Legal status : Ceased

Application number

AU2004285562A

Other languages

English (en)

Other versions

AU2004285562A1 (en

Inventor

Hua Liu

Patrick Tong

Current Assignee

Johns Hopkins University

Original Assignee

Johns Hopkins University

Priority date

2003-10-29

Filing date

2004-10-29

Publication date

2011-06-09

2004-10-29 Application filed by Johns Hopkins University filed Critical Johns Hopkins University

2005-05-12 Publication of AU2004285562A1 publication Critical patent/AU2004285562A1/en

2011-06-09 Application granted granted Critical

2011-06-09 Publication of AU2004285562B2 publication Critical patent/AU2004285562B2/en

2024-10-29 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 91
108090000102 pigment epithelium-derived factor Proteins 0.000 title description 328
230000004071 biological effect Effects 0.000 title description 10
102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 claims description 166
230000008728 vascular permeability Effects 0.000 claims description 65
238000011282 treatment Methods 0.000 claims description 26
125000003275 alpha amino acid group Chemical group 0.000 claims description 25
238000002360 preparation method Methods 0.000 claims description 20
230000001965 increasing effect Effects 0.000 claims description 13
230000002792 vascular Effects 0.000 claims description 12
206010012689 Diabetic retinopathy Diseases 0.000 claims description 11
230000035699 permeability Effects 0.000 claims description 9
206010038923 Retinopathy Diseases 0.000 claims description 8
208000017442 Retinal disease Diseases 0.000 claims description 7
239000000049 pigment Substances 0.000 claims description 7
206010012601 diabetes mellitus Diseases 0.000 claims description 6
206010029164 Nephrotic syndrome Diseases 0.000 claims description 5
206010040047 Sepsis Diseases 0.000 claims description 5
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
208000033679 diabetic kidney disease Diseases 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
102100035846 Pigment epithelium-derived factor Human genes 0.000 description 319
150000001413 amino acids Chemical class 0.000 description 118
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 100
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 97
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 97
210000004027 cell Anatomy 0.000 description 94
239000000203 mixture Substances 0.000 description 87
108090000623 proteins and genes Proteins 0.000 description 63
239000004480 active ingredient Substances 0.000 description 48
235000001014 amino acid Nutrition 0.000 description 45
238000009472 formulation Methods 0.000 description 44
230000000694 effects Effects 0.000 description 43
229940024606 amino acid Drugs 0.000 description 41
239000008194 pharmaceutical composition Substances 0.000 description 38
239000013598 vector Substances 0.000 description 38
210000001519 tissue Anatomy 0.000 description 35
230000033115 angiogenesis Effects 0.000 description 33
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 33
150000007523 nucleic acids Chemical class 0.000 description 33
102000004196 processed proteins & peptides Human genes 0.000 description 32
235000018102 proteins Nutrition 0.000 description 31
102000039446 nucleic acids Human genes 0.000 description 29
108020004707 nucleic acids Proteins 0.000 description 29
102000004169 proteins and genes Human genes 0.000 description 29
239000004615 ingredient Substances 0.000 description 25
230000002207 retinal effect Effects 0.000 description 25
102000001214 HSP47 Heat-Shock Proteins Human genes 0.000 description 24
108010055039 HSP47 Heat-Shock Proteins Proteins 0.000 description 24
125000000539 amino acid group Chemical group 0.000 description 24
239000003795 chemical substances by application Substances 0.000 description 23
-1 ACT Proteins 0.000 description 22
150000001875 compounds Chemical class 0.000 description 22
201000010099 disease Diseases 0.000 description 21
125000003729 nucleotide group Chemical group 0.000 description 21
241001465754 Metazoa Species 0.000 description 18
206010028980 Neoplasm Diseases 0.000 description 18
230000002401 inhibitory effect Effects 0.000 description 18
239000002773 nucleotide Substances 0.000 description 18
230000001772 anti-angiogenic effect Effects 0.000 description 17
230000014509 gene expression Effects 0.000 description 17
108091033319 polynucleotide Proteins 0.000 description 17
102000040430 polynucleotide Human genes 0.000 description 17
239000002157 polynucleotide Substances 0.000 description 17
239000000243 solution Substances 0.000 description 17
238000003556 assay Methods 0.000 description 16
239000012634 fragment Substances 0.000 description 16
239000007924 injection Substances 0.000 description 16
238000002347 injection Methods 0.000 description 16
239000000725 suspension Substances 0.000 description 16
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 15
108020004414 DNA Proteins 0.000 description 15
230000000903 blocking effect Effects 0.000 description 15
210000002889 endothelial cell Anatomy 0.000 description 15
150000002148 esters Chemical class 0.000 description 15
229960003699 evans blue Drugs 0.000 description 14
239000000047 product Substances 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 13
230000010595 endothelial cell migration Effects 0.000 description 13
239000013604 expression vector Substances 0.000 description 13
239000007788 liquid Substances 0.000 description 13
239000002245 particle Substances 0.000 description 13
229920001184 polypeptide Polymers 0.000 description 13
102000008847 Serpin Human genes 0.000 description 12
108050000761 Serpin Proteins 0.000 description 12
230000027455 binding Effects 0.000 description 12
208000035475 disorder Diseases 0.000 description 12
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 12
230000006870 function Effects 0.000 description 12
230000000508 neurotrophic effect Effects 0.000 description 12
239000000126 substance Substances 0.000 description 12
108091034117 Oligonucleotide Proteins 0.000 description 11
239000000463 material Substances 0.000 description 11
230000004048 modification Effects 0.000 description 11
238000012986 modification Methods 0.000 description 11
239000000843 powder Substances 0.000 description 11
239000003001 serine protease inhibitor Substances 0.000 description 11
238000003786 synthesis reaction Methods 0.000 description 11
239000003826 tablet Substances 0.000 description 11
241000124008 Mammalia Species 0.000 description 10
239000002270 dispersing agent Substances 0.000 description 10
238000013508 migration Methods 0.000 description 10
230000003389 potentiating effect Effects 0.000 description 10
239000003755 preservative agent Substances 0.000 description 10
150000003839 salts Chemical class 0.000 description 10
239000002904 solvent Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 9
239000003153 chemical reaction reagent Substances 0.000 description 9
108020004999 messenger RNA Proteins 0.000 description 9
230000005012 migration Effects 0.000 description 9
239000002953 phosphate buffered saline Substances 0.000 description 9
239000013612 plasmid Substances 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
229920005989 resin Polymers 0.000 description 9
239000011347 resin Substances 0.000 description 9
238000006467 substitution reaction Methods 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 8
108091028043 Nucleic acid sequence Proteins 0.000 description 8
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 8
239000003085 diluting agent Substances 0.000 description 8
238000007911 parenteral administration Methods 0.000 description 8
230000001737 promoting effect Effects 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
210000001525 retina Anatomy 0.000 description 8
239000000375 suspending agent Substances 0.000 description 8
238000013268 sustained release Methods 0.000 description 8
239000012730 sustained-release form Substances 0.000 description 8
239000013603 viral vector Substances 0.000 description 8
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
108091033380 Coding strand Proteins 0.000 description 7
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
230000000295 complement effect Effects 0.000 description 7
229930195712 glutamate Natural products 0.000 description 7
230000012010 growth Effects 0.000 description 7
229960000310 isoleucine Drugs 0.000 description 7
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 7
230000000324 neuroprotective effect Effects 0.000 description 7
238000010647 peptide synthesis reaction Methods 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
239000003380 propellant Substances 0.000 description 7
230000001177 retroviral effect Effects 0.000 description 7
235000004400 serine Nutrition 0.000 description 7
238000012360 testing method Methods 0.000 description 7
230000003612 virological effect Effects 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
241000283690 Bos taurus Species 0.000 description 6
150000008574 D-amino acids Chemical class 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
201000000582 Retinoblastoma Diseases 0.000 description 6
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 6
241000700605 Viruses Species 0.000 description 6
230000008901 benefit Effects 0.000 description 6
210000004899 c-terminal region Anatomy 0.000 description 6
239000000839 emulsion Substances 0.000 description 6
235000019441 ethanol Nutrition 0.000 description 6
238000013534 fluorescein angiography Methods 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000003765 sweetening agent Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
238000013518 transcription Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
238000012546 transfer Methods 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
108091026890 Coding region Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
210000004204 blood vessel Anatomy 0.000 description 5
210000001043 capillary endothelial cell Anatomy 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
239000003995 emulsifying agent Substances 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
150000004665 fatty acids Chemical class 0.000 description 5
239000000796 flavoring agent Substances 0.000 description 5
235000003599 food sweetener Nutrition 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
208000028867 ischemia Diseases 0.000 description 5
230000000302 ischemic effect Effects 0.000 description 5
210000002161 motor neuron Anatomy 0.000 description 5
230000035772 mutation Effects 0.000 description 5
230000007935 neutral effect Effects 0.000 description 5
108010072683 pigment epithelium-derived factor receptor Proteins 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
230000002685 pulmonary effect Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000007790 solid phase Substances 0.000 description 5
239000000080 wetting agent Substances 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
201000003883 Cystic fibrosis Diseases 0.000 description 4
KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 4
241000792859 Enema Species 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
235000004279 alanine Nutrition 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000004037 angiogenesis inhibitor Substances 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
235000006708 antioxidants Nutrition 0.000 description 4
239000008135 aqueous vehicle Substances 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
239000003086 colorant Substances 0.000 description 4
229940059082 douche Drugs 0.000 description 4
239000007920 enema Substances 0.000 description 4
229940095399 enema Drugs 0.000 description 4
235000013355 food flavoring agent Nutrition 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
230000013595 glycosylation Effects 0.000 description 4
238000006206 glycosylation reaction Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
239000000411 inducer Substances 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
230000002262 irrigation Effects 0.000 description 4
238000003973 irrigation Methods 0.000 description 4
239000002502 liposome Substances 0.000 description 4
229940057995 liquid paraffin Drugs 0.000 description 4
239000006194 liquid suspension Substances 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000003550 marker Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
238000004806 packaging method and process Methods 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
230000002335 preservative effect Effects 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
238000012545 processing Methods 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
239000000829 suppository Substances 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
235000015112 vegetable and seed oil Nutrition 0.000 description 4
239000008158 vegetable oil Substances 0.000 description 4
BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
235000003911 Arachis Nutrition 0.000 description 3
244000105624 Arachis hypogaea Species 0.000 description 3
201000004569 Blindness Diseases 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
206010012688 Diabetic retinal oedema Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010021143 Hypoxia Diseases 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
208000000592 Nasal Polyps Diseases 0.000 description 3
206010029113 Neovascularisation Diseases 0.000 description 3
240000007817 Olea europaea Species 0.000 description 3
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
208000007135 Retinal Neovascularization Diseases 0.000 description 3
102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 3
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
239000002870 angiogenesis inducing agent Substances 0.000 description 3
230000003042 antagnostic effect Effects 0.000 description 3
230000031018 biological processes and functions Effects 0.000 description 3
210000004155 blood-retinal barrier Anatomy 0.000 description 3
230000004378 blood-retinal barrier Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
238000009835 boiling Methods 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
235000011010 calcium phosphates Nutrition 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000002490 cerebral effect Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
230000032050 esterification Effects 0.000 description 3
238000005886 esterification reaction Methods 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
239000000284 extract Substances 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
239000007902 hard capsule Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
235000010445 lecithin Nutrition 0.000 description 3
239000000787 lecithin Substances 0.000 description 3
229940067606 lecithin Drugs 0.000 description 3
208000002780 macular degeneration Diseases 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000002480 mineral oil Substances 0.000 description 3
239000003226 mitogen Substances 0.000 description 3
239000004006 olive oil Substances 0.000 description 3
235000008390 olive oil Nutrition 0.000 description 3
238000001543 one-way ANOVA Methods 0.000 description 3
230000007170 pathology Effects 0.000 description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
238000007423 screening assay Methods 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
239000002562 thickening agent Substances 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
230000021000 vacuolar transport Effects 0.000 description 3
210000003556 vascular endothelial cell Anatomy 0.000 description 3
230000004393 visual impairment Effects 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
235000006491 Acacia senegal Nutrition 0.000 description 2
235000019489 Almond oil Nutrition 0.000 description 2
241000272517 Anseriformes Species 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
241000271566 Aves Species 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 2
101710145225 Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
101001073422 Homo sapiens Pigment epithelium-derived factor Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
241000714177 Murine leukemia virus Species 0.000 description 2
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
108010025020 Nerve Growth Factor Proteins 0.000 description 2
102000007072 Nerve Growth Factors Human genes 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
101710102218 Serine protease inhibitor Proteins 0.000 description 2
244000000231 Sesamum indicum Species 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
208000002847 Surgical Wound Diseases 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 2
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
230000002411 adverse Effects 0.000 description 2
206010064930 age-related macular degeneration Diseases 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
239000008168 almond oil Substances 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
210000003484 anatomy Anatomy 0.000 description 2
230000002491 angiogenic effect Effects 0.000 description 2
238000000137 annealing Methods 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
201000007917 background diabetic retinopathy Diseases 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
108091006116 chimeric peptides Proteins 0.000 description 2
239000003541 chymotrypsin inhibitor Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
239000003240 coconut oil Substances 0.000 description 2
235000019864 coconut oil Nutrition 0.000 description 2
230000000112 colonic effect Effects 0.000 description 2
239000007859 condensation product Substances 0.000 description 2
230000001143 conditioned effect Effects 0.000 description 2
230000008602 contraction Effects 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
230000006806 disease prevention Effects 0.000 description 2
239000006196 drop Substances 0.000 description 2
239000003974 emollient agent Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000000945 filler Substances 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
230000036543 hypotension Effects 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000002430 laser surgery Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000006193 liquid solution Substances 0.000 description 2
230000004807 localization Effects 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
238000010232 migration assay Methods 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
238000000465 moulding Methods 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
210000002241 neurite Anatomy 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
230000014511 neuron projection development Effects 0.000 description 2
230000004112 neuroprotection Effects 0.000 description 2
239000004090 neuroprotective agent Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000012071 phase Substances 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
201000007914 proliferative diabetic retinopathy Diseases 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004233 retinal vasculature Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000007901 soft capsule Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
210000001578 tight junction Anatomy 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
206010000050 Abdominal adhesions Diseases 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
108091093088 Amplicon Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000003120 Angiofibroma Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
108091062157 Cis-regulatory element Proteins 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
206010058202 Cystoid macular oedema Diseases 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
229930182847 D-glutamic acid Natural products 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
101000827763 Drosophila melanogaster Fibroblast growth factor receptor homolog 1 Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108010041308 Endothelial Growth Factors Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
208000020564 Eye injury Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 1
101000670189 Homo sapiens Ribulose-phosphate 3-epimerase Proteins 0.000 description 1
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
206010058490 Hyperoxia Diseases 0.000 description 1
108010031792 IGF Type 2 Receptor Proteins 0.000 description 1
102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000001344 Macular Edema Diseases 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
108050006616 Mannose-6-phosphate receptors Proteins 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
108010006519 Molecular Chaperones Proteins 0.000 description 1
102000005431 Molecular Chaperones Human genes 0.000 description 1
101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
206010056677 Nerve degeneration Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000012868 Overgrowth Diseases 0.000 description 1
201000010183 Papilledema Diseases 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000286209 Phasianidae Species 0.000 description 1
102000006335 Phosphate-Binding Proteins Human genes 0.000 description 1
108010058514 Phosphate-Binding Proteins Proteins 0.000 description 1
108010003541 Platelet Activating Factor Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
102000018120 Recombinases Human genes 0.000 description 1
108010091086 Recombinases Proteins 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
206010038886 Retinal oedema Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
229940122055 Serine protease inhibitor Drugs 0.000 description 1
101150018337 Serpinh1 gene Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
206010043189 Telangiectasia Diseases 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108091008605 VEGF receptors Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
108010022164 acetyl-LDL Proteins 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
210000001742 aqueous humor Anatomy 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
229960002028 atropine sulfate Drugs 0.000 description 1
230000003376 axonal effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000005395 beveled glass Substances 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229940088623 biologically active substance Drugs 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
238000011685 brown norway rat Methods 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000021523 carboxylation Effects 0.000 description 1
238000006473 carboxylation reaction Methods 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
102000028740 cation-dependent mannose-6-phosphate receptor Human genes 0.000 description 1
108010090156 cation-dependent mannose-6-phosphate receptor Proteins 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000000782 cerebellar granule cell Anatomy 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
208000012191 childhood neoplasm Diseases 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000004087 circulation Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000036570 collagen biosynthesis Effects 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
201000010206 cystoid macular edema Diseases 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000000151 deposition Methods 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
229950006137 dexfosfoserine Drugs 0.000 description 1
201000009101 diabetic angiopathy Diseases 0.000 description 1
201000011190 diabetic macular edema Diseases 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000012631 diagnostic technique Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
JVXZRNYCRFIEGV-UHFFFAOYSA-M dilC18(3) dye Chemical compound [O-]Cl(=O)(=O)=O.CC1(C)C2=CC=CC=C2N(CCCCCCCCCCCCCCCCCC)C1=CC=CC1=[N+](CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2C1(C)C JVXZRNYCRFIEGV-UHFFFAOYSA-M 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000000842 folliculostellate cell Anatomy 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
230000001279 glycosylating effect Effects 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000003780 hair follicle Anatomy 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
238000004896 high resolution mass spectrometry Methods 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
102000058223 human VEGFA Human genes 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
230000000222 hyperoxic effect Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
230000000642 iatrogenic effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
239000004434 industrial solvent Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000010354 integration Effects 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
210000004692 intercellular junction Anatomy 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
238000010829 isocratic elution Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
210000000738 kidney tubule Anatomy 0.000 description 1
TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
108010034897 lentil lectin Proteins 0.000 description 1
230000003902 lesion Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000000865 liniment Substances 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
208000018769 loss of vision Diseases 0.000 description 1
231100000864 loss of vision Toxicity 0.000 description 1
239000006210 lotion Substances 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
238000013507 mapping Methods 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000001617 migratory effect Effects 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
230000004001 molecular interaction Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
SHDMMLFAFLZUEV-UHFFFAOYSA-N n-methyl-1,1-diphenylmethanamine Chemical compound C=1C=CC=CC=1C(NC)C1=CC=CC=C1 SHDMMLFAFLZUEV-UHFFFAOYSA-N 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
230000004031 neuronal differentiation Effects 0.000 description 1
230000007514 neuronal growth Effects 0.000 description 1
230000006576 neuronal survival Effects 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
239000003900 neurotrophic factor Substances 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical group OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
108010016700 plasminogen kringle 5 Proteins 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920006122 polyamide resin Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920005990 polystyrene resin Polymers 0.000 description 1
230000019708 positive regulation of vascular permeability Effects 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000003334 potential effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
150000003141 primary amines Chemical group 0.000 description 1
230000001023 pro-angiogenic effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
208000023958 prostate neoplasm Diseases 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000006920 protein precipitation Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
210000000449 purkinje cell Anatomy 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
238000009877 rendering Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
201000011195 retinal edema Diseases 0.000 description 1
210000001116 retinal neuron Anatomy 0.000 description 1
210000003583 retinal pigment epithelium Anatomy 0.000 description 1
208000004644 retinal vein occlusion Diseases 0.000 description 1
210000001210 retinal vessel Anatomy 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229940085605 saccharin sodium Drugs 0.000 description 1
210000004116 schwann cell Anatomy 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
150000003355 serines Chemical class 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
108091005475 signaling receptors Proteins 0.000 description 1
102000035025 signaling receptors Human genes 0.000 description 1
239000002002 slurry Substances 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
229960005314 suramin Drugs 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
208000009056 telangiectasis Diseases 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000001982 uveitic effect Effects 0.000 description 1
239000004474 valine Substances 0.000 description 1
229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
238000001262 western blot Methods 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1